 Connection
Jesse Schold to Alemtuzumab
This is a "connection" page, showing publications Jesse Schold has written about Alemtuzumab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.194 |
|
|
|
-
Schold J, Poggio E, Goldfarb D, Kayler L, Flechner S. Clinical outcomes associated with induction regimens among retransplant kidney recipients in the United States. Transplantation. 2015 Jun; 99(6):1165-71.
Score: 0.129
-
Koyawala N, Silber JH, Rosenbaum PR, Wang W, Hill AS, Reiter JG, Niknam BA, Even-Shoshan O, Bloom RD, Sawinski D, Nazarian S, Trofe-Clark J, Lim MA, Schold JD, Reese PP. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation. J Am Soc Nephrol. 2017 Jul; 28(7):2188-2200.
Score: 0.037
-
Zachariah M, Gregg A, Schold J, Magliocca J, Kayler LK. Alemtuzumab induction in simultaneous pancreas and kidney transplantation. Clin Transplant. 2013 Sep-Oct; 27(5):693-700.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|